116 related articles for article (PubMed ID: 27685911)
1. Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy.
Karabulut S; Usul Afsar C; Karabulut M; Alis H; Erturk K; Karaman S; Kones O; Bilgin E; Tas F
J BUON; 2016; 21(4):895-902. PubMed ID: 27685911
[TBL] [Abstract][Full Text] [Related]
2. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
Usul Afsar Ç; Karabulut M; Karabulut S; Alis H; Gonenc M; Dagoglu N; Serilmez M; Tas F
J Infect Chemother; 2017 Apr; 23(4):196-200. PubMed ID: 28087305
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.
Karabulut S; Afsar ÇU; Karabulut M; Alış H; Kılıc L; Çikot M; Yasasever CT; Aykan NF
J Gastrointest Cancer; 2016 Mar; 47(1):47-54. PubMed ID: 26637231
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
6. Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine.
Ploquin A; Truant S; Piessen G; Vuagnat P; Baldini C; Cattan S; Hebbar M
In Vivo; 2017; 31(4):731-735. PubMed ID: 28652448
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
Ziske C; Schlie C; Gorschlüter M; Glasmacher A; Mey U; Strehl J; Sauerbruch T; Schmidt-Wolf IG
Br J Cancer; 2003 Oct; 89(8):1413-7. PubMed ID: 14562009
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer.
Afsar CU; Karabulut M; Karabulut S; Ozal ST; Cikot M; Serilmez M; Tas F
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30544746
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
11. Circulating annexin A2 as a biomarker in patients with pancreatic cancer.
Karabulut M; Afsar CU; Serilmez M; Karabulut S
J Cancer Res Ther; 2020 Dec; 16(Supplement):S110-S115. PubMed ID: 33380663
[TBL] [Abstract][Full Text] [Related]
12. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Park I; Choi SJ; Kim YS; Ahn HK; Hong J; Sym SJ; Park J; Cho EK; Lee JH; Shin YJ; Shin DB
Cancer Res Treat; 2016 Oct; 48(4):1264-1273. PubMed ID: 27034148
[TBL] [Abstract][Full Text] [Related]
16. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.
Heinemann V; Schermuly MM; Stieber P; Schulz L; Jüngst D; Wilkowski R; Schalhorn A
Anticancer Res; 1999; 19(4A):2433-5. PubMed ID: 10470171
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
[TBL] [Abstract][Full Text] [Related]
18. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma.
Karabulut S; Afsar CU; Karabulut M; Alis H; Bozkurt MA; Aydogan F; Serilmez M; Tas F
BBA Clin; 2016 Dec; 6():138-142. PubMed ID: 27785418
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
